People with multiple sclerosis (MS) reported improvements in physical and mental quality of life along with reduced depression after one year of treatment with an ocrelizumab biosimilar, according to a small study conducted in Iran. The observational study followed 30 adults with MS who received Xacrel, an ocrelizumab biosimilar approved in Iran, and assessed patient-reported […]
The post MS patients report feeling better after a year of biosimilar treatment appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com